Every so often, a company walks into healthcare like it owns the joint, not with swagger, but with results that leave the competition blinking. Amae Health just did that, locking in a pre-empted $25M Series B led by Altos Ventures, with every existing investor, Quiet Capital, Bling Capital, Cedars-Sinai Ventures, Healthier Capital & 8VC, back in the ring. That’s not a funding round, that’s conviction with receipts.
Founded in Jan 2022 by Stas Sokolin & Sonia Priscilla García, Amae Health isn’t another startup tossing buzzwords into the mental health void. It’s a psychiatry-led, in-person model laser-focused on severe mental illness: schizophrenia, bipolar, treatment-resistant depression, the cases the system usually leaves behind. “Amae,” from Japanese for “depending on others to help you thrive,” isn’t marketing fluff; it’s the thesis. Built as a Public Benefit Corp, they’re in the business of human recovery, not app engagement.
The stats are savage. A 30-day hospital readmission rate under 4% when the national average is 23%. 85%+ med adherence vs 53% industry-wide. 100% post-hospital follow-up. NPS of 90. And 80%+ patient retention that would make any SaaS exec jealous. In a world obsessed with “scale,” Amae Health proves that better care is the scale. Clinics in LA, NYC & Raleigh are humming; Brooklyn, Houston & Ohio are queued up next.
Behind the outcomes is a precision medicine platform built on Palantir Foundry, where AI plays wingman, not overlord. Their Patient-at-a-Glance dashboard gives clinicians a 360° view; their Point-of-Care Assistant flags changes in real time; and their Symptomology Phenotyping personalizes every treatment plan. It’s what happens when tech is designed to serve the doctor, not the dopamine loop.
Stas Sokolin brings a résumé that reads like a masterclass in mission-driven strategy, Chan Zuckerberg Initiative, Google X, Health2047. Sonia Priscilla García blends Stanford d.school creativity with Nike-honed precision and Brightline’s scaling experience. Add Dr. Scott C. Fears, UCLA psychiatrist and neuroscientist, plus Dr. Gary Tsai, a national leader in addiction medicine, and you’ve got a lineup ready to redefine behavioral health.
This $25M isn’t just capital, it’s proof that tackling the hardest problems still pays. With all investors doubling down and Altos Ventures stepping up, Amae Health’s message is clear: AI can be ethical, psychiatry can be scalable, and care can be both clinical and compassionate. They’re not chasing the next health trend, they’re building the blueprint for remission, recovery & maybe, just maybe, a cure.
